Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (573)	7/29/2021 11:56:29 AM
From: scaram(o)uche	Respond to of 684

PDSB..... yesterday's PR...... The release implies that their NCI collaborators have given permission to update trial results at investment conferences, rather than waiting for scientific symposia. Highly out of the norm. This trial..... clinicaltrials.gov Moreover, they point to the excellent results discussed at ASCO, at the high bar that the ASCO data represents. Why would they point to data which sets a very lofty goal in expanded testing? I wouldn't do so, unless I knew that the expanded results are at least in the same league. The PR..... pdsbiotech.com It also sounds as if initial results may be reviewed for this trial??........ clinicaltrials.gov All of this from a company where the CEO is very careful about wording.